Vor Bio Q3 2026 net loss narrows 89% to $86.7 million

• Vor Bio’s third-quarter 2026 net loss narrowed 89% year over year to $86.7 million.
• R&D expenses more than doubled to $34.5 million, while general and administrative expenses rose 71% to $23.9 million year over year.
• Cash, cash equivalents and marketable securities totaled $481.6 million at September 30, expected to fund operations into early 2029.
• Enrollment completed in the Phase 3 UPSTREAM MG trial of telitacicept, with topline results expected in the first half of 2027.
• First patient dosing in the Phase 3 UPSTREAM oMG trial for ocular myasthenia gravis is anticipated in the first half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vor Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610300800PRIMZONEFULLFEED9856642) on October 30, 2026, and is solely responsible for the information contained therein.